IQC	INITIALS	DATE
Cut		
Labelled		
Collated		
QC		
Packaged		

HEALTH SERVICES LABORATORIES
ADVANCED DIAGNOSTICS

Address: HSL-AD, Ground Floor, 60 Whitfield Street, London, W1T 4EU
Tel: +44 (0)20 3912 0280 | **Email:** AD@hslpathology.com | **Web:** www.hsl-ad.com

PD-L1 IHC (ATEZOLIZUMAB, ROCHE SP142, TRIPLE NEGATIVE BREAST CANCER, IC)

FOR LABORATORY USE ONLY

HSL-AD NUMBER:_____ MATERIAL RECEIVED:_____

PRICE (TO BE INVOICED):_____ DATE RECEIVED & INITIALS:_____

PATIENT / SAMPLE DETAILS

SURNAME:_____ SURGICAL CASE ID:_____

FORENAME:_____ TUMOUR TYPE & GRADE (essential): _____

DOB:_____ **M** ☐ **F** ☐ _____

REFERRING HOSPITAL / INVOICING DETAILS

CONSULTANT:_____

ADDRESS:_____

_____

_____

PHONE:_____

INVOICING DETAILS (if different)

CONTACT NAME:_____

ORGANISATION:_____

ADDRESS:_____

_____

PURCHASE NUMBER:_____

REPORT DELIVERY (please tick - faxing of reports will end October 2020) **FAX** ☐ **EMAIL** ☐

FAX NUMBER(S):	EMAIL ADDRESS(ES):
_____	_____
_____	_____

PD-L1 (ATEZOLIZUMAB, ROCHE SP142, TRIPLE NEGATIVE BREAST CANCER) IC IHC REPORT

TUMOUR ASSESSMENT

☐ SUFFICIENT FOR ASSESSMENT

☐ INSUFFICIENT FOR ASSESSMENT

IC SCORE

☐ IC SCORE (%)

RESULT

☐ **NEGATIVE** *(IC <1%)*

☐ **POSITIVE** *(IC ≥1%)*

TEST COMMENTS

INTERPRETATION GUIDE: **This assay is FDA-approved and uses the Roche SP142 kit performed on the Roche Ventana Ultra. This report is for use in Triple Negative Breast Cancer (TNBC) only and is used as a companion diagnostic to indicate the suitability of patient treatment with Atezolizumab. Scoring method used is the tumour-infiltrating Immune Cell Score (IC). The use of Atezolizumab for treatment of TNBC is not currently licensed by NICE. The use of this report for selection of treatment options in other tumour settings has not been validated.**

NEGATIVE (IC <1%): Patient is unlikely to respond to treatment involving Atezolizumab.

POSITIVE (IC ≥1%): Patient may respond to treatment involving Atezolizumab.

SIGNED:_____ **DATE:**_____

Dr Teresa Marafioti / Dr Reena Khiroya